Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,926 | 305 | 1,597 |
| Samples | 372 | 96 | 271 |
| Peptides | 222 | 49 | 180 |
Function
SIRPA · Signal regulatory protein alpha
The protein encoded by this gene is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP family members are receptor-type transmembrane glycoproteins known to be involved in the negative regulation of receptor tyrosine kinase-coupled signaling processes. This protein can be phosphorylated by tyrosine kinases. The phospho-tyrosine residues of this PTP have been shown to recruit SH2 domain containing tyrosine phosphatases (PTP), and serve as substrates of PTPs. This protein was found to participate in signal transduction mediated by various growth factor receptors. CD47 has been demonstrated to be a ligand for this receptor protein. This gene and its product share very high similarity with several other members of the SIRP family. These related genes are located in close proximity to each other on chromosome 20p13. Multiple alternatively spliced transcript variants have been determined for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 213 amino-acid changes on canonical ENST00000358771 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SIRPA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SIRPA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 40/304 13% | 24/1390 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Endometrial Carcinoma | 1/42 2% | 14/612 2% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 12/810 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Colorectal Carcinoma | 4/143 3% | 48/3239 1% |
| Bladder Carcinoma | 0/58 0% | 12/956 1% |
| Meningioma | 0/3 0% | 3/252 1% |
| Other Solid Cancers | 1/94 1% | 18/1515 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 8/752 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 17/1592 1% |
| Gastric Carcinoma | 2/74 3% | 16/1809 1% |
| Neuroendocrine Tumour | 7/154 5% | 0/577 0% |
| Melanoma | 1/210 0% | 17/1899 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 13/2550 1% |
| Glioma | 1/52 2% | 11/2127 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Head and Neck Carcinoma | 4/85 5% | 3/1574 0% |
| Pancreatic Carcinoma | 2/89 2% | 5/1611 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 5/2534 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Biliary Tract Carcinoma | 2/54 4% | 1/950 0% |
Mutation Distribution
Where SIRPA is mutated · all tissues, split by cell line vs tissue
How many mutations in SIRPA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,926 mutations in SIRPA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|